Literature DB >> 18544732

Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.

Karyn Hede.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18544732     DOI： 10.1093/jnci/djn200

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  26 in total

Review 1.  Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers.

Authors:  Lien Tembuyser; Elisabeth M C Dequeker
Journal:  Virchows Arch       Date:  2015-08-26       Impact factor: 4.064

2.  Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.

Authors:  Allison W Welsh; Christopher B Moeder; Sudha Kumar; Peter Gershkovich; Elaine T Alarid; Malini Harigopal; Bruce G Haffty; David L Rimm
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Multiplex immunoassays of peptide hormones extracted from formalin-fixed, paraffin-embedded tissue accurately subclassify pituitary adenomas.

Authors:  Frederick G Strathmann; Grace Borlee; Donald E Born; Luis F Gonzalez-Cuyar; Bertrand R Huber; Geoffrey S Baird
Journal:  Clin Chem       Date:  2011-12-28       Impact factor: 8.327

4.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Authors:  D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5.

Authors:  Allison W Welsh; Malini Harigopal; Hallie Wimberly; Manju Prasad; David L Rimm
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-03

6.  Osteoporosis after breast cancer chemotherapy: a case report.

Authors:  Giovanni Sisti; Olga Prontera
Journal:  Ochsner J       Date:  2009

7.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.

Authors:  Malini Harigopal; William E Barlow; Greg Tedeschi; Peggy L Porter; I-Tien Yeh; Charles Haskell; Robert Livingston; Gabriel N Hortobagyi; George Sledge; Charles Shapiro; James N Ingle; David L Rimm; Daniel F Hayes
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

8.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

Authors:  Ian J Majewski; René Bernards
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

9.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

10.  An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

Authors:  Jelle Wesseling; Corrado Tinterri; Anna Sapino; Fabrizio Zanconati; Martijn Lutke-Holzik; Bichlien Nguyen; Kenneth B Deck; Patrizia Querzoli; Tiziana Perin; Carmela Giardina; Gerhard Seitz; Jean-Marc Guinebretière; Julie Barone; Laura Dekker; Femke de Snoo; Lisette Stork-Sloots; Paul Roepman; Toru Watanabe; Pino Cusumano
Journal:  Virchows Arch       Date:  2016-07-04       Impact factor: 4.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.